Pharmaron Beijing Co., Ltd.

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 2026-01-21			5-day change	1st Jan Change
30.87 ^CNY	-0.16%		-5.97%	+8.58%

Jan. 14	Pharmaron Beijing to place 58.4 million new H shares at RMB1.00 per share	RE
Jan. 14	Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering	MT

Pharmaron Beijing Co., Ltd.'s Equity Buyback announced on December 16, 2024, has expired.

Published on 06/04/2025

S&P Capital IQ

PHARMARON BEIJING CO., LTD.

-0.16%

The company expired its plan on June 5, 2025.

Latest news about Pharmaron Beijing Co., Ltd.

Jan. 14	Pharmaron Beijing to place 58.4 million new H shares at RMB1.00 per share	RE
Jan. 14	Pharmaron Beijing Seeking HK$1.33 Billion via Stock Offering	MT
Jan. 14	Pharmaron to raise HK$1.3 billion in share placement	RE
Jan. 13	Pharmaron Beijing Expects Lower 2025 Profit	MT
Jan. 13	Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2025	CI
Jan. 13	Pharmaron Beijing sees 2025 net profit down 6-10%	RE
Dec. 18	Pharmaron Beijing Co., Ltd. Announces Election of Mr. Li Shing Chung Gilbert as Employee Representative Director Effective December 18, 2025	CI
25-10-28	Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-28	Pharmaron Beijing Co., Ltd. Announces Resignation of Tsang Kwan Hung Benson as Independent Non-Executive Director	CI
25-10-28	Pharmaron Beijing Q3 net profit up 42.5% Y/Y	RE
25-10-27	Pharmaron Beijing Co., Ltd. agreed to acquire 3.08% stake in Wuxi Biortus Biosciences Co. Ltd. from Jiangyin Baiao Management Consulting Enterprise (Limited Partnership), Jiangyin Baisheng Management Consulting Center (Limited Partnership), Jiangyin Baichuang Management Consulting Center (Limited Partnership) and Jiangyin Baiying Management Consulting Center (Limited Partnership), Wu Jiaquan for CNY 27.2 million.	CI
25-09-15	Pharmaron's Shaoxing Unit Passes US FDA On-Site Inspection	MT
25-09-15	Pharmaron Beijing announces passing of U.S. FDA on-site inspection- by Pharmaron Shaoxing	RE
25-08-25	Jefferies Adjusts Pharmaron Beijing's Price Target to HK$28 From HK$22, Keeps at Buy	MT
25-08-22	Pharmaron Beijing H1 Profit Falls 37%, Revenue Rises 15%	MT
25-08-22	Nomura Adjusts Pharmaron Beijing's Price Target to 34.62 Yuan From 33.75 Yuan, Keeps at Buy	MT
25-08-22	Nomura Adjusts Pharmaron Beijing's Price Target to HK$26.63 From HK$25.86, Keeps at Buy	MT
25-08-21	Pharmaron Beijing's H1 Profit Falls 37%	MT
25-08-21	Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-21	Pharmaron Beijing reports HY aggregate revenue of RMB6,441.0 million	RE
25-07-16	Nomura Adjusts Pharmaron Beijing's Price Target to 33.75 Yuan From 33.31 Yuan, Keeps at Buy	MT
25-07-16	Nomura Adjusts Pharmaron Beijing's Price Target to HK$25.86 From HK$16.19, Keeps at Buy	MT
25-07-16	Hong Kong Stocks Fall as Trade Uncertainty Looms, HKMA Steps In to Defend Currency Peg	MT
25-07-15	Pharmaron Beijing Expects Up to 39% Drop in H1 Profit; Shares Decline 4%	MT
25-07-15	Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2025	CI

Chart Pharmaron Beijing Co., Ltd.

Duration

Period

300759: Dynamic Chart

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Employees

21,370

Sector

Biotechnology & Medical Research

Calendar

Mar. 29 - Q4 2025 Earnings Release (Projected)

More about the company